Abstract
Background: Peenisam (sinusitis) is a widespread condition, and patients are visiting Ayothidass Pandithar Hospital, National Institute of Siddha, to manage this condition. The signs and symptoms of peenisam (sinusitis) are mentioned in Siddha literature Yugi vaithya chinthamani, such as lacrimation, nasal block, headache, rhinorrhea, cough, absence of taste, may be correlated with maxillary sinusitis in biomedicine. Objectives: To evaluate the clinical effectiveness of Siddha formulations Sombu theeneer (internal) and Peenisathirku thailam (external) in the management of sinusitis by using Adelaide Disease Severity Score (ADSS) and to observe changes in clinical lab parameters, total count, differential count, erythrocyte sedimentation rate, absolute eosinophil count and serum immunoglobulin E pre and post-treatment. Methods: An open Non-Randomised clinical trial with a sample size of 10 patients diagnosed with Peenisam within the age limit of 18-60 years. The approval was obtained from Institutional Ethical Committee for conducting this clinical study with the IEC No: (25/11/2021; NIS/IEC/2021/MP-3). It was registered prospectively in the Clinical Trail Registry of India (CTRI Reg No: CTRI/2022/01/051045). The trial drug Sombu theeneer (internal) 30 ml BD with water after food and Peenisathirku thailam (external) were given for 48 days and two months follow up without the trial drug. Results: Biostatistical reports of ADSS scores and lab investigations before and after treatment were statistically analysed using paired t-tests. There was a significant reduction in both the ADSS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Research in Ayurveda and Pharmacy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
